Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 3.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 29,380 shares of the medical research company's stock after selling 1,147 shares during the period. AQR Capital Management LLC owned approximately 0.10% of Bio-Rad Laboratories worth $9,652,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Perbak Capital Partners LLP purchased a new stake in Bio-Rad Laboratories during the fourth quarter worth approximately $1,379,000. Northern Trust Corp raised its stake in Bio-Rad Laboratories by 24.3% during the 4th quarter. Northern Trust Corp now owns 260,868 shares of the medical research company's stock worth $85,698,000 after acquiring an additional 51,048 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Bio-Rad Laboratories by 23.5% in the fourth quarter. The Manufacturers Life Insurance Company now owns 107,195 shares of the medical research company's stock valued at $35,215,000 after acquiring an additional 20,413 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in Bio-Rad Laboratories in the fourth quarter valued at $2,442,000. Finally, Earnest Partners LLC increased its position in shares of Bio-Rad Laboratories by 2.1% during the fourth quarter. Earnest Partners LLC now owns 618,049 shares of the medical research company's stock worth $203,035,000 after purchasing an additional 12,500 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Price Performance

Shares of BIO stock traded up $14.10 during mid-day trading on Monday, reaching $252.78. The stock had a trading volume of 52,066 shares, compared to its average volume of 315,758. The company has a market cap of $7.08 billion, a P/E ratio of -3.89 and a beta of 1.00. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12-month low of $215.38 and a 12-month high of $387.99. The business has a 50-day simple moving average of $244.34 and a 200 day simple moving average of $301.12.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The business had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. During the same period in the prior year, the business earned $2.30 earnings per share. The business's revenue was down 4.2% on a year-over-year basis. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BIO shares. Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. UBS Group lowered their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Royal Bank of Canada dropped their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Citigroup lowered their price objective on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and an average price target of $327.40.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.